Modality
Gene Editing
MOA
CAR-T BCMA
Target
WEE1
Pathway
Sphingolipid
DravetSLE
Development Pipeline
Preclinical
Nov 2017
→ Mar 2030
PreclinicalCurrent
NCT07926747
963 pts·SLE
2021-02→2030-03·Recruiting
NCT06919289
1,241 pts·SLE
2017-11→2029-01·Not yet recruiting
2,204 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-01-152.8y awayInterim· SLE
2030-03-083.9y awayInterim· SLE
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Not yet…
Preclinical
Recruit…
Catalysts
Interim
2029-01-15 · 2.8y away
SLE
Interim
2030-03-08 · 3.9y away
SLE
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07926747 | Preclinical | SLE | Recruiting | 963 | PASI75 |
| NCT06919289 | Preclinical | SLE | Not yet recr... | 1241 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA |